FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309442885> ?p ?o ?g. }

• W4309442885 endingPage "389" @default.
• W4309442885 startingPage "376" @default.
• W4309442885 abstract "Normalisation of blood glucose in individuals with diabetes is recommended to reduce development of diabetic complications. However, risk of severe hypoglycaemia with intensive insulin therapy is a major obstacle that prevents many individuals with diabetes from obtaining the recommended reduction in HbA1c. Inhibition of glucagon receptor signalling and liver-preferential insulin action have been shown individually to have beneficial effects in preclinical models and individuals with diabetes (i.e. improved glycaemic control), but also have effects that are potential safety risks (i.e. alpha cell hyperplasia in response to glucagon receptor antagonists and increased levels of liver triacylglycerols and plasma alanine aminotransferase activity in response to glucagon receptor antagonists and liver-preferential insulin). We hypothesised that a combination of glucagon inhibition and liver-preferential insulin action in a dual-acting molecule would widen the therapeutic window. By correcting two pathogenic mechanisms (dysregulated glucagon signalling and non-physiological distribution of conventional insulin administered s.c.), we hypothesised that lower doses of each component would be required to obtain sufficient reduction of hyperglycaemia, and that the undesirable effects that have previously been observed for monotreatment with glucagon antagonists and liver-preferential insulin could be avoided.A dual-acting glucagon receptor inhibitor and liver-preferential insulin molecule was designed and tested in rodent models (normal rats, rats with streptozotocin-induced hyperglycaemia, db/db mice and mice with diet-induced obesity and streptozotocin-induced hyperglycaemia), allowing detailed characterisation of the pharmacokinetic and pharmacodynamic properties of the dual-acting molecule and relevant control compounds, as well as exploration of how the dual-acting molecule influenced glucagon-induced recovery and spontaneous recovery from acute hypoglycaemia.This molecule normalised blood glucose in diabetic models, and was markedly less prone to induce hypoglycaemia than conventional insulin treatment (approximately 4.6-fold less potent under hypoglycaemic conditions than under normoglycaemic conditions). However, compared to treatment with conventional long-acting insulin, this dual-acting molecule also increased triacylglycerol levels in the liver (approximately 60%), plasma alanine aminotransferase levels (approximately twofold) and alpha cell mass (approximately twofold).While the dual-acting glucagon receptor inhibitor and liver-preferential insulin molecule showed markedly improved regulation of blood glucose, effects that are potential safety concerns persisted in the pharmacologically relevant dose range." @default.
• W4309442885 created "2022-11-27" @default.
• W4309442885 creator A5001309622 @default.
• W4309442885 creator A5004445787 @default.
• W4309442885 creator A5010666668 @default.
• W4309442885 creator A5013301991 @default.
• W4309442885 creator A5013888878 @default.
• W4309442885 creator A5014875708 @default.
• W4309442885 creator A5039010803 @default.
• W4309442885 creator A5039553849 @default.
• W4309442885 creator A5045538726 @default.
• W4309442885 creator A5052013163 @default.
• W4309442885 creator A5059122884 @default.
• W4309442885 creator A5061239123 @default.
• W4309442885 creator A5061560702 @default.
• W4309442885 creator A5063442000 @default.
• W4309442885 creator A5074062112 @default.
• W4309442885 creator A5076238081 @default.
• W4309442885 creator A5077872121 @default.
• W4309442885 creator A5084986320 @default.
• W4309442885 creator A5086335599 @default.
• W4309442885 creator A5086471334 @default.
• W4309442885 creator A5086494090 @default.
• W4309442885 creator A5064489612 @default.
• W4309442885 date "2022-11-21" @default.
• W4309442885 modified "2023-10-18" @default.
• W4309442885 title "Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models" @default.
• W4309442885 cites W1526927233 @default.
• W4309442885 cites W1805517524 @default.
• W4309442885 cites W1942547537 @default.
• W4309442885 cites W1972243514 @default.
• W4309442885 cites W1986874694 @default.
• W4309442885 cites W2004870840 @default.
• W4309442885 cites W2011063859 @default.
• W4309442885 cites W2025993954 @default.
• W4309442885 cites W2026582363 @default.
• W4309442885 cites W2027083357 @default.
• W4309442885 cites W2035336727 @default.
• W4309442885 cites W2044025814 @default.
• W4309442885 cites W2050103781 @default.
• W4309442885 cites W2053311112 @default.
• W4309442885 cites W2068377236 @default.
• W4309442885 cites W2095995901 @default.
• W4309442885 cites W2097781567 @default.
• W4309442885 cites W2097995302 @default.
• W4309442885 cites W2111824270 @default.
• W4309442885 cites W2113278846 @default.
• W4309442885 cites W2115282607 @default.
• W4309442885 cites W2123946565 @default.
• W4309442885 cites W2125430658 @default.
• W4309442885 cites W2127167047 @default.
• W4309442885 cites W2149121623 @default.
• W4309442885 cites W2158666727 @default.
• W4309442885 cites W2207556001 @default.
• W4309442885 cites W2337454357 @default.
• W4309442885 cites W2469322296 @default.
• W4309442885 cites W2489491424 @default.
• W4309442885 cites W2531213507 @default.
• W4309442885 cites W2549302673 @default.
• W4309442885 cites W2579298009 @default.
• W4309442885 cites W2600127085 @default.
• W4309442885 cites W2748151984 @default.
• W4309442885 cites W2762892866 @default.
• W4309442885 cites W2765700591 @default.
• W4309442885 cites W2769264260 @default.
• W4309442885 cites W2779666226 @default.
• W4309442885 cites W2909166675 @default.
• W4309442885 cites W2911935607 @default.
• W4309442885 cites W2915730620 @default.
• W4309442885 cites W2947644232 @default.
• W4309442885 cites W2968464804 @default.
• W4309442885 cites W2968803386 @default.
• W4309442885 cites W3009231969 @default.
• W4309442885 cites W3046603383 @default.
• W4309442885 cites W4235701932 @default.
• W4309442885 doi "https://doi.org/10.1007/s00125-022-05828-w" @default.
• W4309442885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36404376" @default.
• W4309442885 hasPublicationYear "2022" @default.
• W4309442885 type Work @default.
• W4309442885 citedByCount "1" @default.
• W4309442885 countsByYear W43094428852023 @default.
• W4309442885 crossrefType "journal-article" @default.
• W4309442885 hasAuthorship W4309442885A5001309622 @default.
• W4309442885 hasAuthorship W4309442885A5004445787 @default.
• W4309442885 hasAuthorship W4309442885A5010666668 @default.
• W4309442885 hasAuthorship W4309442885A5013301991 @default.
• W4309442885 hasAuthorship W4309442885A5013888878 @default.
• W4309442885 hasAuthorship W4309442885A5014875708 @default.
• W4309442885 hasAuthorship W4309442885A5039010803 @default.
• W4309442885 hasAuthorship W4309442885A5039553849 @default.
• W4309442885 hasAuthorship W4309442885A5045538726 @default.
• W4309442885 hasAuthorship W4309442885A5052013163 @default.
• W4309442885 hasAuthorship W4309442885A5059122884 @default.
• W4309442885 hasAuthorship W4309442885A5061239123 @default.
• W4309442885 hasAuthorship W4309442885A5061560702 @default.
• W4309442885 hasAuthorship W4309442885A5063442000 @default.
• W4309442885 hasAuthorship W4309442885A5064489612 @default.
• W4309442885 hasAuthorship W4309442885A5074062112 @default.

• next